KURA Q2 2025 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M

Gross Profit

$15M100.0% margin

Operating Income

-$73M-475.3% margin

Net Income

-$66M-432.5% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

+8.4%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$682M

Total Liabilities

$377M

Stockholders' Equity

$305M

Cash & Equivalents

$82M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$0	—
Gross Profit	$15M	-$202,000	+7668.3%
Operating Income	-$73M	-$56M	-28.8%
Net Income	-$66M	-$51M	-30.1%

Revenue Segments

Operating Segments

$15M100%